It is known that peripheral neuropathy as an unwanted side effect of the anticancer drug oxaliplatin, especially cold allodynia, which reacts hypersensitively to cold stimuli, greatly impairs the QOL of patients. Therefore, it is desired to develop preventive or therapeutic medicines for cold allodynia. Previous studies have shown that pituitary adenylate cyclase-activating polypeptide (PACAP) antagonists have potent effects in preventing cold allodynia in in vivo studies. In this study, we evaluated the adverse effects of oxaliplatin and their protective effects using an extracellular potential measurement system using rat E14 primary dorsal root ganglion cells (DRG). The effect of oxaliplatin and antagonist of PAC1, that is a PACAP receptor, on extracellular action potential was verified. The firing frequency of extracellular action potential increased in a concentration-dependent manner with oxaliplatin. On the other hand, the addition of PAC1 antagonists abolished the firing of the extracellular potential. Moreover, the firing of PAC1-treated DRG neuron decreased compared to before addition of oxaliplatin. The evaluation system for peripheral neuropathy caused by anticancer drugs by measuring the extracellular potential of DRG was able to show the usefulness as a system that can evaluate side effects in the acute phase.